Ixekizumab‐induced urticarial drug eruption
Abstract Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL‐17A, which exhibited high...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2023-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a8535a90de2e4ebfa12f1ae8d558c6b2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ayaka Kaneoka |e author |
| 700 | 1 | 0 | |a Natsuko Saito‐Sasaki |e author |
| 700 | 1 | 0 | |a Etsuko Okada |e author |
| 700 | 1 | 0 | |a Yu Sawada |e author |
| 245 | 0 | 0 | |a Ixekizumab‐induced urticarial drug eruption |
| 260 | |b Wiley, |c 2023-10-01T00:00:00Z. | ||
| 500 | |a 2690-442X | ||
| 500 | |a 10.1002/ski2.271 | ||
| 520 | |a Abstract Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL‐17A, which exhibited high efficacy against psoriasis. Although there are a limited number of cutaneous adverse reactions, biologic‐induced type I allergic reactions are rare. Herein, we report a case of ixekizumab‐induced urticaria. | ||
| 546 | |a EN | ||
| 690 | |a Dermatology | ||
| 690 | |a RL1-803 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Skin Health and Disease, Vol 3, Iss 5, Pp n/a-n/a (2023) | |
| 787 | 0 | |n https://doi.org/10.1002/ski2.271 | |
| 787 | 0 | |n https://doaj.org/toc/2690-442X | |
| 856 | 4 | 1 | |u https://doaj.org/article/a8535a90de2e4ebfa12f1ae8d558c6b2 |z Connect to this object online. |